Zurcher Kantonalbank Zurich Cantonalbank Buys 1,106 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Zurcher Kantonalbank Zurich Cantonalbank raised its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 14.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,541 shares of the company’s stock after purchasing an additional 1,106 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in SI-BONE were worth $179,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. RiverPark Advisors LLC acquired a new position in SI-BONE during the 3rd quarter worth approximately $55,000. Arizona State Retirement System raised its position in shares of SI-BONE by 7.7% during the fourth quarter. Arizona State Retirement System now owns 10,675 shares of the company’s stock worth $224,000 after purchasing an additional 762 shares during the period. HighMark Wealth Management LLC bought a new position in shares of SI-BONE in the 4th quarter worth $399,000. Glenmede Trust Co. NA acquired a new stake in SI-BONE in the 3rd quarter valued at $417,000. Finally, Barclays PLC increased its stake in SI-BONE by 63.2% during the 3rd quarter. Barclays PLC now owns 24,286 shares of the company’s stock valued at $516,000 after purchasing an additional 9,402 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Stock Performance

NASDAQ SIBN opened at $15.68 on Wednesday. The company has a market capitalization of $646.02 million, a PE ratio of -13.75 and a beta of 1.24. The company has a debt-to-equity ratio of 0.21, a quick ratio of 8.15 and a current ratio of 9.01. SI-BONE, Inc. has a 52-week low of $13.96 and a 52-week high of $29.51. The company has a 50-day simple moving average of $15.83 and a 200 day simple moving average of $18.01.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. The company had revenue of $38.86 million during the quarter, compared to analyst estimates of $38.60 million. On average, research analysts predict that SI-BONE, Inc. will post -0.98 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the completion of the transaction, the chief financial officer now owns 205,516 shares in the company, valued at approximately $3,175,222.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total transaction of $37,466.25. Following the completion of the transaction, the chief financial officer now owns 205,516 shares in the company, valued at $3,175,222.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,307 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $15.50, for a total transaction of $51,258.50. Following the completion of the sale, the insider now directly owns 252,453 shares in the company, valued at approximately $3,913,021.50. The disclosure for this sale can be found here. Insiders sold 11,905 shares of company stock valued at $190,273 over the last ninety days. 5.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

SIBN has been the subject of a number of recent research reports. Truist Financial reissued a “buy” rating and set a $24.00 price objective (down from $26.00) on shares of SI-BONE in a report on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a report on Tuesday, February 27th. Morgan Stanley lowered their price target on SI-BONE from $26.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 price objective on shares of SI-BONE in a report on Tuesday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of SI-BONE in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SI-BONE has an average rating of “Buy” and a consensus price target of $27.29.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.